Condition: Influenza · Sponsor: Jiangxi Qingfeng Pharmaceutical Co. Ltd.
Index patients who are infected with influenza virus (Q-PCR positive) can be treated with anti-influenza drugs if their influenza symptoms onset was within 48 hours of screening. Their eligible households will be randomized to either GP681 tablets or placebo if at least 1 household contacts have not received influenza vaccine with 6 months of screening and if all household contacts screen negative for influenza infection. The main endpoints are assessed based on multiple respiratory swabs, obtained from household contacts up to Day 10, and through the assessment of symptoms.
This description comes directly from the study's public registry record.
Siyuan Xi · 84206250 · ZRYHYYGCPEC@126.com
Bin Cao, phd · 13911318339 · caobin_ben@163.com
Always discuss trial participation with your own doctor first.
| Shulan (Hang Zhou) Hospital | Hanzhou, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06574503